All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10324549" target="_blank" >RIV/00064165:_____/16:10324549 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11110/16:10324549

  • Result on the web

    <a href="http://biomed.papers.upol.cz/pdfs/bio/2016/01/01.pdf" target="_blank" >http://biomed.papers.upol.cz/pdfs/bio/2016/01/01.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.5507/bp.2016.003" target="_blank" >10.5507/bp.2016.003</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    HMGB1, S100 proteins and other RAGE ligands in cancer - markers, mediators and putative therapeutic targets

  • Original language description

    Background and Aims. Activation of RAGE due to its increased expression in cancer cells or its stimulation by multiple ligands (AGEs, HMGB1, S100 proteins, etc.) may contribute to the proliferation, invasiveness of tumor cells and formation of distant metastases and also to the resistance of cancer to treatment. RAGE ligands could thus become both useful markers of disease severity and its outcome and, a potential therapeutic target. Conclusions. Better understanding of the role of RAGE activation in different types of cancer may help to define the role of ligand/RAGE antagonists as promising cancer treatment.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FD - Oncology and haematology

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Biomedical Papers

  • ISSN

    1213-8118

  • e-ISSN

  • Volume of the periodical

    160

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    10

  • Pages from-to

    1-10

  • UT code for WoS article

    000373390800001

  • EID of the result in the Scopus database

    2-s2.0-84962469623